New York, Feb 6, 2026, 11:09 (EST) — Regular session
- Three companies priced their IPOs late Thursday and are set to begin trading on U.S. exchanges Friday.
- Early action in this week’s fresh listings has been uneven, as investors swiftly back momentum and shun signs of weakness.
- Two blank-check flotations were trading near $10 a share, highlighting the persistent caution in the “easy money” segment of the IPO market.
Once Upon a Farm, the children’s food brand connected to actress Jennifer Garner, is gearing up for its NYSE debut on Friday. The company priced its U.S. IPO at $18 per share.
Friday’s slate may not be a blockbuster, but it offers a clear snapshot of risk appetite — with consumer, biotech, and blank-check stocks all hitting the market. The day counts because the IPO pipeline is trying to hold firm, even as stocks jitter and investors grow selective about what they buy or skip. Finviz
At least one potential issuer is pulling back. Liftoff Mobile, a Blackstone-backed mobile app marketing company, postponed its IPO, citing a need for “additional time before listing” amid current market conditions. The move underscores how crucial timing remains this week. Barron’s
Once Upon a Farm announced the sale of 10,997,209 shares at $18 each, with some shares coming from existing shareholders. The company intends to use the funds to repay debt, purchase equipment, and support other corporate expenses. Goldman Sachs and J.P. Morgan are steering the transaction. Business Wire
Belgian biotech AgomAb Therapeutics, which specializes in immunology and inflammatory diseases, set its IPO price at $16 per American depositary share — those U.S.-listed certificates that stand for foreign company stock. The company plans to start trading on Nasdaq under the ticker AGMB. Nasdaq
SpyGlass Pharma, a developer focused on eye-disease treatments, set its IPO price at $16 per share and plans to list on Nasdaq under the ticker SGP. The company aims to advance long-acting drug delivery solutions for chronic eye diseases, particularly those linked to glaucoma. markets.businessinsider.com
Late this morning in New York, the three new tickers remained absent from delayed screens, indicating underwriters hadn’t kicked off any opening trades yet. Finviz
On the IPO front, two SPACs held near their $10 debut prices. Cambridge Acquisition’s units hovered at $9.98, with SPACSphere’s units just above at $10.04. Finviz
The week kicked off with a mixed bag of debuts. Electrical equipment maker Forgent Power Solutions, which pulled in $1.51 billion in its IPO, gained roughly 8.4% to $31.44. Furniture retailer Bob’s Discount Furniture climbed 5.6% to $17.98, while biotech firm Eikon Therapeutics slipped 1.2% to $14.82. Reuters
A rough opening remains the simplest risk. If Friday’s new issues debut under their offering price—or fail to attract solid volume after listing—it could quickly dampen sentiment in the pipeline, particularly as the market continues to digest volatile rate forecasts and major earnings reports.
The next hurdle for investors is straightforward and urgent: will the initial trades settle for OFRM, AGMB, and SGP? And can they maintain their offer prices into the afternoon as liquidity ramps up?
